Modelling data for: Short-course combination treatment for experimental chronic Chagas disease
Authors/Creators
- 1. GlaxoSmithKline (Spain)
- 2. University of Dundee
Description
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, affects millions of people in the Americas and across the world leading to considerable morbidity and mortality. Current treatment options, benznidazole (BNZ) and nifurtimox, offer limited efficacy and often lead to adverse side effects due to long treatment durations. Better treatment options are therefore urgently required. Here we describe a pyrrolopyrimidine series, identified through phenotypic screening, that offers a clear opportunity to improve on current treatments. In vitro cell-based washout assays demonstrate that compounds in the series are incapable of killing all parasites, however, combining these pyrrolopyrimidines with a sub-efficacious dose of BNZ can clear all parasites in vitro after five days. Importantly, these findings were replicated in a clinically predictive in vivo model of chronic Chagas disease, where five days of treatment with the combination was sufficient to prevent parasite relapse. Comprehensive mechanism of action studies, supported by ligand-structure modelling, show that compounds from this pyrrolopyrimidine series inhibit the Qi active site of T. cruzi cytochrome b, part of the cytochrome bc1 complex of the electron transport chain. Knowledge of the molecular target enabled a cascade of assays to be assembled to evaluate selectivity over the human cytochrome b homologue. As a result, a highly selective and efficacious lead compound was identified. The combination of our lead compound with BNZ rapidly clears T. cruzi parasites, both in vitro and in vivo, and shows great potential to overcome key issues associated with currently available treatments.
Notes
Methods
Protein and ligand preparation for molecular modelling
Our molecular modelling studies were based on a previously generated homology model of T. cruzi cytochrome b. The protein structure with a conserved water molecule interacting with F33 was prepared using the Protein Preparation module in the Schrödinger suite (Schrödinger Release 2021-2). Protonation states were assigned by PROPKA at pH 7.0, and the hydrogen bonding network was consequently optimized. A restrained energy minimization step was then executed using the OPLS4 force field with default settings. Models of cytochrome b bearing either L197I or F222L mutations were prepared in Maestro by mutating one residue at a time. Subsequently, the mutated versions of cytochrome b were processed with the Protein Preparation tool in an identical manner to the wild-type enzyme.
Ligand structures (compounds 1-4) were prepared with Schrödinger's LigPrep (Schrödinger Release 2021-2). All possible tautomeric forms and stereoisomers were generated at pH 7.0 ± 0.4 using Epik.
Docking studies
Molecular docking studies were carried out using Glide Standard Precision (SP) mode (Schrödinger Release 2021-2). First, the docking grid boxes were generated using the Receptor Grid Generation tool; bound ubiquinone (UQ2) was selected as the center of the grid, and a cube of 10 Å was defined as the inner box. During docking, a total of 20 poses per ligand were subjected to post-docking minimization, and a maximum of ten docking poses for each ligand were output. This setup was able to successfully reproduce the experimentally determined binding mode of antimycin A.
Molecular dynamic simulation
Molecular Dynamic (MD) simulation of the binding mode generated by molecular docking was carried out to analyze the stability of the pose and the interactions at the binding site. The docking pose of compound 3 in complex with T. cruzi cytochrome b was used as the initial coordinate for the generation of the MD system. Desmond software (Schrödinger Release 2021-2) was utilized to set up the system and run the MD simulation. As cytochrome b is embedded in the inner mitochondrial membrane, MD was performed in membrane; thus, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) membranes were added to the model system by placing the two layers automatically. The system was then solvated using the SPC (simple point-charge) water model in a Periodic Boundary Conditions orthorhombic box and neutralized with Na+ ions at a salt concentration of 0.15 M. The option "exclude ions and salt placement" was turned on to allow a 10 Å buffer zone from the ligand. The default Desmond protocol for energy minimization and model relaxation was applied before performing the production simulation. The OPLS4 force field and NPAT (constant particle number (N), pressure (P), lateral surface area (A), and temperature (T)) ensemble were used. The temperature was kept constant at 300 K, while the pressure was kept at 1.01325 bar. Lastly, a 100 ns MD simulation with a trajectory interval of 5 ps was carried out with the same conditions. Simulation Interactions Diagram (SID) was used for the analysis of the MD simulation. The RMSF and RMSD values were then plotted using R packages.
Files
FigS12-A.csv
Files
(22.0 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:0252ad3d413b5417d1e5dccbc9bb023b
|
528.3 kB | Download |
|
md5:e9e1740205bd28defd0a208d6b990b66
|
528.3 kB | Download |
|
md5:527bbaa30a813e4a54355c5f9c71e586
|
528.3 kB | Download |
|
md5:ec3ac94460c7172a5d789f888b39ee17
|
528.7 kB | Download |
|
md5:fea64706948f68a5502351cbaf86b17c
|
502.9 kB | Download |
|
md5:4e48fc1fb47cc24f591c3e970a96b6ac
|
536.1 kB | Download |
|
md5:253a426a50ee08e8946108c18580f3a9
|
1.3 MB | Download |
|
md5:a6454366ca4daff32ac9ef8b906e4dd5
|
1.5 MB | Download |
|
md5:2c6cfda106472f6c0f4c5a0528ae7f13
|
449.1 kB | Preview Download |
|
md5:df12a1f8ea877d0bc95eb3d764db5a65
|
528.3 kB | Download |
|
md5:6df0bc732c94d96400c882722629421b
|
528.3 kB | Download |
|
md5:2e324c9e6300957d47502f6dabf8b9c6
|
528.3 kB | Download |
|
md5:5f07c63db5dad2a3bf64869356e7c469
|
528.3 kB | Download |
|
md5:0f13f416f71f01a36ca308baaa4e0967
|
528.3 kB | Download |
|
md5:253a426a50ee08e8946108c18580f3a9
|
1.3 MB | Download |
|
md5:6c2a3fa9ab30ffeee2d703431894dc54
|
1.6 MB | Download |
|
md5:97d7be38472329695613d68bc74e2c63
|
545 Bytes | Download |
|
md5:a6454366ca4daff32ac9ef8b906e4dd5
|
1.5 MB | Download |
|
md5:00405c13ddd53a697dd14163831b7e32
|
3.8 MB | Download |
|
md5:1bc8f9affb05999943d0f5dec72c1498
|
524.3 kB | Download |
|
md5:19ef83e7029de9235a3a69a23e508774
|
524.3 kB | Download |
|
md5:629dd57e7960a6a0d3eb76ad6a4968cd
|
524.2 kB | Download |
|
md5:f29368d3990fc43247ff725bc08af1d4
|
528.3 kB | Download |
|
md5:ca2375ec757429a6f6431b2c35bcf906
|
528.3 kB | Download |
|
md5:cbfc2796449a9281480c73eb61bdf8cb
|
528.3 kB | Download |
|
md5:2ccaacef04e8f823380f8e6e3403dd60
|
528.3 kB | Download |
|
md5:644d7327f04bc67fd78fd3150a809eb7
|
528.7 kB | Download |
|
md5:8f6d9c1248d77e481da1bdf6eab9aa59
|
4.1 kB | Download |
|
md5:c530bc3cdfc20f0c000e5986d2198b0e
|
4.1 kB | Download |
|
md5:fc5e1db6fae85e1ff42145bf265a034b
|
4.1 kB | Download |
|
md5:87f3df007b0891069cf48d6fa5c5bd4a
|
524.3 kB | Download |
|
md5:e417141e7269d215ac0e4c893f88c13e
|
5.6 kB | Preview Download |